Agenus (NASDAQ:AGEN) Raised to Strong-Buy at Wall Street Zen

Agenus (NASDAQ:AGEN) was upgraded by investment analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Sunday.

Several other analysts have also recently commented on the company. Zacks Research cut Agenus from a “strong-buy” rating to a “hold” rating in a report on Monday, May 11th. HC Wainwright lifted their price target on shares of Agenus from $23.00 to $30.00 and gave the company a “buy” rating in a research note on Monday, July 13th. B. Riley Financial restated a “buy” rating and set a $14.00 price objective (up from $8.00) on shares of Agenus in a report on Thursday, July 30th. Finally, Weiss Ratings raised shares of Agenus from a “sell (d)” rating to a “sell (d+)” rating in a research report on Friday. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Agenus currently has a consensus rating of “Hold” and an average price target of $22.00.

Agenus Stock Up 0.6%

NASDAQ:AGEN opened at $7.00 on Friday. The firm has a market capitalization of $313.25 million, a PE ratio of 2.71 and a beta of 1.40. Agenus has a twelve month low of $2.71 and a twelve month high of $8.85. The stock’s 50-day simple moving average is $4.54 and its 200 day simple moving average is $3.84.

Agenus (NASDAQ:AGEN) last posted its quarterly earnings results on Monday, May 11th. The biotechnology company reported $1.02 earnings per share for the quarter, missing analysts’ consensus estimates of $2.10 by ($1.08). The company had revenue of $33.74 million during the quarter, compared to analyst estimates of $129.50 million. Agenus had a net margin of 69.33% and a negative return on equity of 45.12%. On average, analysts anticipate that Agenus will post -0.2 EPS for the current fiscal year.

Institutional Investors Weigh In On Agenus

A number of institutional investors and hedge funds have recently bought and sold shares of AGEN. EP Wealth Advisors LLC purchased a new position in Agenus during the fourth quarter worth about $31,000. Jump Financial LLC bought a new stake in Agenus during the second quarter worth $55,000. R Squared Ltd purchased a new position in Agenus in the fourth quarter worth $41,000. Squarepoint Ops LLC purchased a new position in Agenus in the third quarter worth $54,000. Finally, Redwood Family Wealth LLC bought a new position in Agenus in the 4th quarter valued at $44,000. 61.46% of the stock is owned by hedge funds and other institutional investors.

About Agenus

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.